Publications by authors named "David Amato"

Claim this Profile
A
Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies.
April Armstrong, David Amato, William Huster, Clement Ojeh, Abby S Van Voorhees

J Am Acad Dermatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato

J Am Acad Dermatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sick and unsheltered: Homelessness as a major risk factor for emergency care utilization.
Stas Amato, Flavia Nobay, David Petty Amato, Beau Abar, David Adler

Am J Emerg Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.
Joseph F Merola, David A Amato, Kyoungah See, Russel Burge, Craig Mallinckrodt

J Invest Dermatol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Sarah Al Sawah, Shonda A Foster, Russel Burge, David Amato, Alexander Schacht

J Med Econ· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermatologists: Collaborating With Payers to Optimize Coverage Policies.
David A Amato, William N Malatestinic, Matthew C Palmgren, Steven R Feldman

J Drugs Dermatol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
Ellen B Dennehy, Lu Zhang, David Amato, Orin Goldblum, Phoebe Rich

J Drugs Dermatol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, David Amato

N Engl J Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
April W Armstrong, Charles W Lynde, Sandy R McBride, Mona Ståhle, Emily Edson-Heredia, David Amato

JAMA Dermatol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
Arian Pano, Ann J Barbier, Bonnie Bielefeld, David A H Whiteman, David A Amato

Orphanet J Rare Dis· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Raphael Schiffmann, Markus Ries, Derek Blankenship, Kathy Nicholls, Atul Mehta, David Amato

Genet Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Robert E Kalb, Andrew Blauvelt, Howard L Sofen, Marc Chevrier, David Amato

J Drugs Dermatol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study.
Thomas Roth, Janet M Price, David A Amato, Robert P Rubens, James M Roach

Prim Care Companion J Clin Psychiatry· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Robert C Green, Lon S Schneider, David A Amato, Andrew P Beelen, Gordon Wilcock

JAMA· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Milton K Erman, Gary Zammit, Robert Rubens, Kendyl Schaefer, Thomas Wessel, David Amato

J Clin Sleep Med· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome.
Russell Rosenberg, James M Roach, Martin Scharf, David A Amato

Sleep Med· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
James K Walsh, Andrew D Krystal, David A Amato, Robert Rubens, Judy Caron

Sleep· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Maurizio Fava, W Vaughn McCall, Andrew Krystal, Thomas Wessel, Robert Rubens, David Amato

Biol Psychiatry· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.
Martin Scharf, Milton Erman, Russell Rosenberg, David Seiden, W Vaughn McCall, David Amato

Sleep· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
Russell Rosenberg, Judy Caron, Thomas Roth, David Amato

Sleep Med· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.
Gary K Zammit, Louis J McNabb, Judy Caron, David A Amato, Thomas Roth

Curr Med Res Opin· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
Andrew D Krystal, James K Walsh, Eugene Laska, Judy Caron, David A Amato

Sleep· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis